Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
trending now
trending in pharma/biotech
trending in device
pharmagather
advertise
Legal Help
login/register
You are here
Home
»
companies
» JNJ
JNJ
J&J snags rights to a gene therapy portfolio from little MeiraGTx, a spinoff from Sam Waksal’s Kadmon
J&J snags rights to a gene therapy portfolio from little MeiraGTx, a spinoff from Sam Waksal’s Kadmon
Endpoints
JNJ
MeiraGTx
gene therapy
Flag link:
FDA approves J&J’s Tremfya self-injection pen for psoriasis
FDA approves J&J’s Tremfya self-injection pen for psoriasis
Drug Delivery Business News
JNJ
FDA
Tremfya
psoriasis
Flag link:
J&J scores another PhIII win for Erleada as it continues to build a blockbuster franchise
J&J scores another PhIII win for Erleada as it continues to build a blockbuster franchise
Endpoints
JNJ
Erleada
prostate cancer
metastatic prostate cancer
Flag link:
3 Big Pharmas Expecting a Softer 2019
3 Big Pharmas Expecting a Softer 2019
Motley Fool
JNJ
AbbVie
Pfizer
Flag link:
Intuitive Surgical Clobbered On Mounting Expenses As J&J, Medtronic Loom
Intuitive Surgical Clobbered On Mounting Expenses As J&J, Medtronic Loom
Investors Business Daily
devices
robotic surgery
Intuitive Surgical
Medtronic
JNJ
Flag link:
Amid controversies, J&J voted most admired pharma
Amid controversies, J&J voted most admired pharma
Biopharma Dive
JNJ
Flag link:
Does Johnson & Johnson's Grim Outlook Spell Trouble for Big Pharma Stocks?
Does Johnson & Johnson's Grim Outlook Spell Trouble for Big Pharma Stocks?
Motley Fool
JNJ
Big Pharma
pharma stocks
Flag link:
J&J may nab surgical robotics company Auris Health
J&J may nab surgical robotics company Auris Health
Mass Device
devices
M&A
JNJ
Auris Health
robotic surgery
Flag link:
J&J CEO: We Know We Still Have More Work to Do [in Devices]
J&J CEO: We Know We Still Have More Work to Do [in Devices]
Medical Devices and Diagnostics Industry
JNJ
earnings
devices
Alex Gorsky
Flag link:
J&J, Attorneys General Settle Hip Implant Allegations for $120m
J&J, Attorneys General Settle Hip Implant Allegations for $120m
RAPS.org
JNJ
DePuy
hip implants
metal-on-metal hip implants
Flag link:
Discounting hit J&J's Xarelto hard. Can a new launch turn things around?
Discounting hit J&J's Xarelto hard. Can a new launch turn things around?
Fierce Pharma
JNJ
earnings
Xarelto
Flag link:
Johnson & Johnson tops fourth-quarter expectations but signals sales to slow this year
Johnson & Johnson tops fourth-quarter expectations but signals sales to slow this year
CNBC
JNJ
earnings
Flag link:
Johnson & Johnson, AbbVie superstar Imbruvica flunks pancreatic cancer test
Johnson & Johnson, AbbVie superstar Imbruvica flunks pancreatic cancer test
Fierce Pharma
AbbVie
JNJ
Imbruvica
pancreatic cancer
clinical trials
Flag link:
Johnson & Johnson Is Trying to Recover From Plunge
Johnson & Johnson Is Trying to Recover From Plunge
Investopedia
JNJ
earnings
Flag link:
Apple and Johnson & Johnson collaborating on heart research project
Apple and Johnson & Johnson collaborating on heart research project
Marketwatch
Apple
JNJ
Janssen
atrial fibrillation
Apple Watch
wearables
devices
Flag link:
European Commission Approves Janssen's Erleada for Patients at High Risk of Developing Metastatic Prostate Cancer
European Commission Approves Janssen's Erleada for Patients at High Risk of Developing Metastatic Prostate Cancer
CP Wire
Janssen
JNJ
Erleada
prostate cancer
Europe
Flag link:
European Commission Approves Janssen's Erleada for Patients at High Risk of Developing Metastatic Prostate Cancer
Janssen
JNJ
Erleada
prostate cancer
Flag link:
J&J hikes US prices for a basket of drugs, including certain top-sellers
J&J hikes US prices for a basket of drugs, including certain top-sellers
Endpoints
JNJ
drug pricing
Flag link:
JP Morgan's Dimon hosted a private dinner for pharma executives, and a major topic was Amazon
JP Morgan's Dimon hosted a private dinner for pharma executives, and a major topic was Amazon
CNBC
JNJ
Pfizer
Eli Lilly
Jamie Dimon
Amazon
JPMHC 2019
Flag link:
J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis
J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis
Fierce Pharma
JNJ
JPMHC 2019
immunology
psoriasis
Tremfya
Flag link:
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »